Diffuse large B-cell lymphoma
Not recruitingStudy on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant
Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant
- Disease:Diffuse large B-cell lymphoma
- Substances:GlofitamabMaplirpacept+1
Germany- Participants:18–64 years · 65+ years
- Substances:Glofitamab
- Sponsor:Pfizer Inc.










